

Utkast til innspill i forbindelse med EFSA's Offentlige høring av mais MON 89034 x 1507 x NK603 x DAS-40278-9 (EFSA-GMO-NL-2013-112)

Innspill fra mat & fôr -gruppen (diskutert på møtet 6 februar 2017)

Food and feed safety assessment

1. The applicant has not provided data that exclude possible combined effects of the newly expressed proteins in the stacked event. Different modes of action do not necessarily exclude interaction.
2. The Norwegian scientific committee would recommend that the applicant performs a 28-day repeated dose toxicity study to assess combined effects of the transgenic proteins.
3. Most immunologic adjuvant experiments on Cry –proteins have been performed on Cry1Ac, and some of these studies have indicated adjuvant properties (VKM, 2012). To our knowledge Cry1A.105, Cry1F and Cry2Ab2 proteins have not been studied experimentally for potential adjuvant properties. Although these proteins do not show sequence resemblance to known adjuvants like cholera toxin and E. coli heat-labile enterotoxin, the VKM GMO Panel highlights the need for further clarification on the potential role of these proteins as adjuvants as part of the risk assessment. This may be of particular importance for high-protein fractions, e.g. maize gluten meal, produced under low temperatures, since levels of the transgenic proteins are up-concentrated in these fractions (as shown in Table 57 in the Technical Dossier).
4. The Norwegian scientific committee would recommend that the applicant performs a nutritional feeding study with animals, e.g. broilers, that could be fed a high inclusion of unprocessed maize in their diets, to assess combined effects of the transgenic proteins.